Pharmaceuticals, Biotechnology and Life Sciences
Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or…
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy…
Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs.…
VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of…
– Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and…
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant…
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no Dose-Limiting Toxicities in…
Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001…
Figure 1 Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib Monotherapy With or Without CXCR4…
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8…